eprintid: 22059
rev_number: 12
eprint_status: archive
userid: 1589
dir: disk0/00/02/20/59
datestamp: 2016-11-02 12:51:30
lastmod: 2021-06-15 20:45:28
status_changed: 2016-11-02 12:51:30
type: article
metadata_visibility: show
creators_name: Jarius, Sven
creators_name: Ruprecht, Klemens
creators_name: Kleiter, Ingo
creators_name: Borisow, Nadja
creators_name: Asgari, Nasrin
creators_name: Pitarokoili, Kalliopi
creators_name: Pache, Florence
creators_name: Stich, Oliver
creators_name: Beume, Lena-Alexandra
creators_name: Hümmert, Martin W.
creators_name: Trebst, Corinna
creators_name: Ringelstein, Marius
creators_name: Aktas, Orhan
creators_name: Winkelmann, Alexander
creators_name: Buttmann, Mathias
creators_name: Schwarz, Alexander
creators_name: Zimmermann, Hanna
creators_name: Brandt, Alexander U.
creators_name: Franciotta, Diego
creators_name: Capobianco, Marco
creators_name: Kuchling, Joseph
creators_name: Haas, Jürgen
creators_name: Korporal-Kuhnke, Mirjam
creators_name: Lillevang, Soeren Thue
creators_name: Fechner, Kai
creators_name: Schanda, Kathrin
creators_name: Paul, Friedemann
creators_name: Wildemann, Brigitte
creators_name: Reindl, Markus
title: MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin
subjects: 610
divisions: 712000
divisions: 911100
abstract: Background: Antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) have been suggested to play a role in a subset of patients with neuromyelitis optica and related disorders.   Objective: To assess (i) the frequency of MOG-IgG in a large and predominantly Caucasian cohort of patients with optic neuritis (ON) and/or myelitis; (ii) the frequency of MOG-IgG among AQP4-IgG-positive patients and vice versa; (iii) the origin and frequency of MOG-IgG in the cerebrospinal fluid (CSF); (iv) the presence of MOG-IgG at disease onset; and (v) the influence of disease activity and treatment status on MOG-IgG titers.   Methods: 614 serum samples from patients with ON and/or myelitis and from controls, including 92 follow-up samples from 55 subjects, and 18 CSF samples were tested for MOG-IgG using a live cell-based assay (CBA) employing full-length human MOG-transfected HEK293A cells.   Results: MOG-IgG was detected in 95 sera from 50 patients with ON and/or myelitis, including 22/54 (40.7%) patients with a history of both ON and myelitis, 22/103 (21.4%) with a history of ON but no myelitis and 6/45 (13.3%) with a history of longitudinally extensive transverse myelitis but no ON, and in 1 control patient with encephalitis and a connective tissue disorder, all of whom were negative for AQP4-IgG. MOG-IgG was absent in 221 further controls, including 83 patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and 85 with multiple sclerosis (MS). MOG-IgG was found in 12/18 (67%) CSF samples from MOG-IgG-seropositive patients; the MOG-IgG-specific antibody index was negative in all cases, indicating a predominantly peripheral origin of CSF MOG-IgG. Serum and CSF MOG-IgG belonged to the complement-activating IgG1 subclass. MOG-IgG was present already at disease onset. The antibodies remained detectable in 40/45 (89%) follow-up samples obtained over a median period of 16.5 months (range 0–123). Serum titers were higher during attacks than during remission (p < 0.0001), highest during attacks of simultaneous myelitis and ON, lowest during acute isolated ON, and declined following treatment.   Conclusions: To date, this is the largest cohort studied for IgG to human full-length MOG by means of an up-to-date CBA. MOG-IgG is present in a substantial subset of patients with ON and/or myelitis, but not in classical MS. Co-existence of MOG-IgG and AQP4-IgG is highly uncommon. CSF MOG-IgG is of extrathecal origin. Serum MOG-IgG is present already at disease onset and remains detectable in the long-term course. Serum titers depend on disease activity and treatment status.
date: 2016
publisher: BioMed Central
id_scheme: DOI
ppn_swb: 1655238353
own_urn: urn:nbn:de:bsz:16-heidok-220593
language: eng
bibsort: JARIUSSVENMOGIGGINNM2016
full_text_status: public
publication: Journal of Neuroinflammation
volume: 13
number: 279
place_of_pub: London
pagerange: 1-16
issn: 1742-2094
citation:   Jarius, Sven ; Ruprecht, Klemens ; Kleiter, Ingo ; Borisow, Nadja ; Asgari, Nasrin ; Pitarokoili, Kalliopi ; Pache, Florence ; Stich, Oliver ; Beume, Lena-Alexandra ; Hümmert, Martin W. ; Trebst, Corinna ; Ringelstein, Marius ; Aktas, Orhan ; Winkelmann, Alexander ; Buttmann, Mathias ; Schwarz, Alexander ; Zimmermann, Hanna ; Brandt, Alexander U. ; Franciotta, Diego ; Capobianco, Marco ; Kuchling, Joseph ; Haas, Jürgen ; Korporal-Kuhnke, Mirjam ; Lillevang, Soeren Thue ; Fechner, Kai ; Schanda, Kathrin ; Paul, Friedemann ; Wildemann, Brigitte ; Reindl, Markus  (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.  Journal of Neuroinflammation, 13 (279).  pp. 1-16.  ISSN 1742-2094     
document_url: https://archiv.ub.uni-heidelberg.de/volltextserver/22059/1/12974_2016_Article_717.pdf